Angina (Angina Pectoris) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 81 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Angina (Angina Pectoris) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Angina (Angina Pectoris) - Pipeline Review, H2 2014', provides an overview of the Angina (Angina Pectoris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Angina (Angina Pectoris) Overview 8
Therapeutics Development 9
Pipeline Products for Angina (Angina Pectoris) - Overview 9
Pipeline Products for Angina (Angina Pectoris) - Comparative Analysis 10
Angina (Angina Pectoris) - Therapeutics under Development by Companies 11
Angina (Angina Pectoris) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Angina (Angina Pectoris) - Products under Development by Companies 16
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 17
Bayer AG 17
Mesoblast Limited 18
Juventas Therapeutics, Inc. 19
CJ CheilJedang Corp. 20
Lacer, S.A. 21
ViroMed Co., Ltd. 22
Kuhnil Pharmaceutical Co., Ltd. 23
Milestone Pharmaceuticals, Inc. 24
LegoChem Biosciences, Inc 25
Cardiolynx AG 26
TSH Biopharm Corporation Limited 27
Hemostemix Ltd 28
Angina (Angina Pectoris) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
alferminogene tadenovec - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VM-202 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VM-202 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CJ-30059 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ACP-01 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Organic Nitrate for Angina Pectoris - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CLC-1201 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
JVS-100 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CEP-41750 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LA-8045 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MSP-2017 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BAY-606583 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CLC1280 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KI-1007 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
R-06 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Angina (Angina Pectoris) - Recent Pipeline Updates 60
Angina (Angina Pectoris) - Dormant Projects 69
Angina (Angina Pectoris) - Discontinued Products 70
Angina (Angina Pectoris) - Product Development Milestones 71
Featured News & Press Releases 71
Nov 07, 2013: Omeros Announces Positive Data in Phase 1 Clinical Trial with OMS721 71
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 72
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 73
Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280 75
Apr 02, 2012: Ranbaxy's Mohali SEZ Facility Begins Export Of Atorvastatin To US Market 76
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 76
Mar 18, 2011: Cytokinetics Announces Fundamental Research In Field Of Cardiac Myosin Activation Published In Journal Science 77
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 78
Dec 15, 2009: New Indication for Procoralan: Use in Combination With Beta Blockers for Chronic Stable Angina Patients. 78
Nov 17, 2009: Higher Dose Of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths And Hospitalizations Due To Heart Failure In Investigational Study 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products under Development for Angina (Angina Pectoris), H2 2014 9
Number of Products under Development for Angina (Angina Pectoris) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2014 17
Angina (Angina Pectoris) - Pipeline by Mesoblast Limited, H2 2014 18
Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2014 19
Angina (Angina Pectoris) - Pipeline by CJ CheilJedang Corp., H2 2014 20
Angina (Angina Pectoris) - Pipeline by Lacer, S.A., H2 2014 21
Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2014 22
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2014 23
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2014 24
Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2014 25
Angina (Angina Pectoris) - Pipeline by Cardiolynx AG, H2 2014 26
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Limited, H2 2014 27
Angina (Angina Pectoris) - Pipeline by Hemostemix Ltd, H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Angina (Angina Pectoris) Therapeutics - Recent Pipeline Updates, H2 2014 60
Angina (Angina Pectoris) - Dormant Projects, H2 2014 69
Angina (Angina Pectoris) - Discontinued Products, H2 2014 70